Breast cancer
Pharmacological Myristoylation Inhibition by Zelenirstat Disrupts Growth Signalling, Energy Metabolism, and Migration in Triple-Negative Breast Cancer Cells
By Pain R, Beauchamp E, Duckett S and 5 others.
Abstract
Background
Metastatic breast cancer cells rely on oxidative phosphorylation (OXPHOS) for energy production, yet selectively targeting mitochondrial metabolism in cancer cells remains a major therapeutic challenge. Myristoylation, the modification of proteins with the 14-carbon fatty acid myristate by N-myristoyltransferases NMT1 and NMT2, dually impacts cancer cell signalling and metabolism. The pan-NMT inhibitor zelenirstat selectively inhibits these enzymes to prevent the myristoylation of target proteins.